The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase 1 study of sorafenib and irinotecan in pediatric patients with relapsed or refractory solid tumors.
Holly Jane Meany
No relevant relationships to disclose
Jeffrey Dome
No relevant relationships to disclose
Pamela S. Hinds
No relevant relationships to disclose
Rochelle Bagatell
No relevant relationships to disclose
Suzanne Shusterman
No relevant relationships to disclose
Brigitte C. Widemann
No relevant relationships to disclose
Emily Stern
No relevant relationships to disclose
Wendy B. London
No relevant relationships to disclose
AeRang Kim
No relevant relationships to disclose
Elizabeth Fox
No relevant relationships to disclose
Carlos Rodriguez-Galindo
No relevant relationships to disclose
Jane E. Minturn
No relevant relationships to disclose